diaDexus, Inc. – ‘8-K’ for 11/14/03

On:  Monday, 11/17/03, at 7:57pm ET   ·   As of:  11/18/03   ·   For:  11/14/03   ·   Accession #:  1169232-3-6718   ·   File #:  0-26483

in

this entire Filing. an “Entity” Search.

Show

Documents searched

and

each “hit”. the 1st “hit”.

↓↑Hints

Current Report   —   Form 8-K
Filing Table of Contents

Document/Exhibit                   Description                      Pages   Size 

 1: 8-K         Current Report                                         3      9K 
 2: EX-99.1     Press Release                                          2     14K 

8-K   —   Current Report
Document Table of Contents

8-K
1st Page of 3
TOC
↑Top
Previous
Next
↓Bottom
Just 1st
 
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

 -------------------------

FORM 8-K

CURRENT REPORT

 Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934

 Date of Report (Date of earliest event reported): November 14, 2003

VAXGEN, INC.
(Exact name of Registrant as Specified in its Charter)

    DELAWARE                       0-26483                94-3236309
(State or other jurisdiction of  (Commission File Number)    (I.R.S. Employer   
 incorporation or organization)                           Identification Number)

 1000 MARINA BLVD., SUITE 200 BRISBANE, CALIFORNIA 94005
 (Address of Principal Administrative Offices)

 Registrants Telephone Number, Including Area Code: (650) 624-1000

8-K
2nd Page of 3
TOC
1st
Previous
Next
↓Bottom
Just 2nd
Item 5.  Other Events and Regulation FD Disclosure.                             

On November 14, 2003, VaxGen, Inc. issued a press release entitled, 
"VaxGen Will Restate Accounting Treatment for Warrants; Company Intends to      
Announce Third-Quarter Results on or Before Nov. 20".                           

This press release is attached as Exhibit 99.1 to this report and is
incorporated herein by reference.                                               

Item 7.  Financial Statements, Pro Forma Financial Information and Exhibits.    

(c) Exhibits.                                                       

Exhibit No.                Description                                          
-----------                -----------                                          

   99.1      Press release dated November 14, 2003, entitled, "VaxGen Will
             Restate Accounting Treatment for Warrants; Company Intends to
     Announce Third-Quarter Results on or Before Nov. 20".

8-K
Last Page of 3
TOC
1st
Previous
Next
↓Bottom
Just 3rd
 SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the        
registrant has duly caused this report to be signed on its behalf by the        
undersigned hereunto duly authorized.                                           

                                                    VaxGen, Inc.
                                                    (Registrant)

Dated: November 17, 2003                        By:   /s/ Carter A. Lee         
                                                     ---------------------------
                                    Carter Lee
                                               Senior Vice President
                                                  Finance & Administration

Dates Referenced Herein   and   Documents Incorporated by Reference

				Referenced-On Page
This ‘8-K’ Filing		Date		First		Last			Other Filings
Filed as of:		11/18/03
Filed on:		11/17/03		3					NT 10-Q
For Period End:		11/14/03		1		2
									List all Filings